2014

Obtained CFDA Class III medical device registration certificate for our lubricant eye drop product which was the only chitosan-based Class III medical device in China for eye protection.

2013

Obtained CFDA Class III medical device registration certificate for Matrifill® which was the first mono-phase cross-linked sodium hyaluronate gel approved by CFDA.

2013

Obtained CFDA Class III medical device registration certificate for our chitosan orthopedics intra-articular injection, which was the only Class III medical device CFDA registration certificate for orthopedics intra-articular injection in China.
 

2009

Proprietary medical chitosan technology was awarded the Second Prize for the National Science and Technology Progress Award.

2002

rhEGF was awarded the Second Price for National Science and Technology Progress Award.

2001

Developed and obtained CFDA Class I new drug registration certificate for our rhEGF products, which were the first approved rhEGF products in the world.

1997

Developed the first generation chitosan, which we believe was the first patented medical chitosan product for use in human body in the world.